Atopic Eczema

Published Date : Nov 2023
Category : Chronic Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Atopic Eczema – The Allergist’s Guide to Optimize Care

Atopic Dermatitis: From Diagnosis to Treatment

Atopic Eczema (atopic dermatitis) is the most common chronic inflammatory skin disease. It causes inflammation, redness, and skin irritation. It is a common condition that generally begins in childhood; however, anyone is affected by the disease at any age. Atopic dermatitis is not a contagious disease, so it cannot spread from person to person. Skin with atopic dermatitis becomes extremely itchy. Additional redness, swelling, cracking, "weeping" clear fluid, crusting, and scaling result from scratching. There are periods when the disease is worse, known as flares, and times when the skin clears up completely, known as remissions. In developed countries, atopic eczema is seen in approximately 10% to 30% of children and 2% to 10% of adults as stated by NCBI. This chronic disorder allied with pruritus usually starts in infancy and presents with dry skin, eczematous lesions, and lichenification. It is supposed that Atopic dermatitis (AD) is associated with other IgE-associated disorders like allergic rhinitis, asthma, and food allergies. AD has substantial morbidity, and it appears that the prevalence of the disorder has been increasing over the past few decades.

The most common symptom of atopic eczema is itching. Other common atopic dermatitis eczema symptoms included are - red, dry patches of skin, rashes that ooze, weep clear fluid, or bleed when scratched as well as thickening and hardening of the skin. The atopic eczema symptoms show in multiple areas of the body at the same time and appear in the same locations and new locations. The appearance and location of the rash differ depending on age; however, the rash appears anywhere on the body. Patients with darker skin tones often experience darkening or lightening of the skin in areas of skin inflammation.

No one knows what the atopic dermatitis causes are. However, researchers know that variations in the protective layer of the skin cause it to lose moisture. Researchers found that the following contribute to the changes in the skin barrier, which helps control moisture changes (mutations) in genes, problems with the immune system, and exposure to certain things in the environment like exposure to tobacco smoke, and certain types of air pollutants. If there is a family history of atopic dermatitis, hay fever, or asthma then, the chance of developing atopic dermatitis atopy is higher. It is more common in non-Hispanic black children and women and girls tend to develop the disease slightly more than men and boys do.

According to NCBI, in developed countries, atopic dermatitis is seen in approximately 10% to 30% of children and 2% to 10% of adults. This incidence has increased two to three times in recent decades. Atopic eczema has a higher incidence at higher latitudes, which is linked to decreased sun exposure and lower humidity levels. Atopic dermatitis is divided into three divisions based on the age of onset:

  • Early-onset atopic dermatitis (birth to 2 years old): It is the most common type of atopic dermatitis, with approximately 60% of cases starting by age 1. 60% of cases resolve by 12 years old.
  • Late-onset atopic dermatitis: Symptoms begin after the onset of puberty.
  • Senile onset atopic dermatitis: An unusual subset with onset in patients older than 60 years old.

The development of new techniques and novel products for the atopic dermatitis eczema treatment and diagnosis of Atopic Eczema has been considered an essential part of increasing the opportunities for the industry player. As a result, it contributes to the outsourcing of the expanding items.

DiseaseLandscape Insights assists in making informed judgments in the field of medical technology, medicines, and diagnostics, where different technologies and spectacular breakthroughs will alter the landscape, resulting in increased growth.

Atopic Eczema Diagnostic Analysis:

For diagnosis of Atopic Eczema, a practitioner takes a patient's history and focuses on the following parameters: medical history, including family history of allergies, having diseases such as hay fever, asthma, or food allergies. Sleep problems, previous treatments for skin-related symptoms. Use of steroids or other medications. Exposure to irritants, such as soaps and detergents, perfumes and cosmetics, and cigarette smoke. Examining skin and the rash. Laboratory tests, such as blood tests to check for other atopic eczema causes of the rash, skin biopsy of the rash, or lesion.

Onset and distribution of lesions, severity of pruritus (e.g., keeping patient awake at night), family and personal history of the atopic triad, and presence of contact allergens.

Atopic dermatitis is classically a clinical diagnosis that gives the classic distribution of lesions in each age group. The presence of related findings (e.g., keratosis pilaris) simplifies diagnosis. A biopsy shows an eczematous pattern. In childhood cases that are recalcitrant to treatment, fluorescent enzyme immunoassays or skin prick testing is performed to detect immunoglobulin E (IgE) antibodies against specific allergens, which is a clinically relevant exacerbating factor.

DiseaseLandscape Insights provides data on current market participants and their products to gain a better knowledge of market dynamics, and it also helps industry leaders with the development of different diagnostic kits and the use of new technologies to improve current diagnostic procedures. DLI services help companies stay competitive, manage the industry's complicated needs, and improve public health by improving Atopic eczema diagnostics.

Diagnostic Market Players:



Edges Medicare Private Limited


Advin Health Care

Biopsy Needle



Iscon Surgical Limited

Biopsy Needle


Biopsy Gun


Cytocore Biopsy Gun

Medtech Devices

Biopsy Gun


Atopic Eczema Treatment Analysis:

Treatments for atopic eczema help to simplify the symptoms. Although there is no known eczema dermatitis treatment, many kids realize that as they age, their symptoms get better on their own. Atopic dermatitis treatments usually include a combination of therapies and include medications, skincare, and phototherapy.

Medications - The doctor prescribes one or more of the following medications to treat eczema atopic dermatitis, depending on the severity of the disease and age of a person:

  • Emollients (moisturizers) –It is used every day to stop the skin from becoming dry.
  • Topical corticosteroids – Atopic dermatitis cream is hydrocortisone cream and eczema ointment decrease inflammation and is commonly used to treat skin diseases.
  • Oral steroids - In severe cases, healthcare providers prescribe prednisone or other oral corticosteroids to help control inflammation. These drugs are only used short-term due to potential side effects, like high blood sugar, glaucoma, slowed growth in kids, and slower wound healing.
  • Dupilumab (Dupixent) - This is a new, FDA-approved injectable medication that treats people with severe atopic dermatitis who haven’t had success with other treatment options.
  • Antibiotics, antivirals, or antifungals - If atopic dermatitis becomes infected, the healthcare provider prescribes these medications to eliminate infection and relieve symptoms.

Skincare - Keeping the skin hydrated by applying eczema moisturizer immediately after bathing to hold the water in the skin is important when treating atopic dermatitis. In some cases, doctors also recommend the following skin care for AD:

To treat AD a diluted bleach bath twice a week is taken. It is important to follow the doctor’s specific instructions when taking a bleach bath. Should not use this treatment without consulting a doctor.

Wet wrap therapy is done to help increase moisture in the skin when the condition is determined. However, only use wet wraps after consulting with a doctor.

Phototherapy - If the atopic dermatitis is severe, widespread, and has not responded to cream and ointment treatments, the doctor recommends using ultraviolet A or B light waves to treat symptoms. Those who experience severe flare-ups following conventional therapy frequently find relief with light therapy. During this treatment, healthcare providers will use controlled amounts of ultraviolet rays on the skin. This type of therapy isn’t recommended long term, as it eventually increases the risk for skin cancer and premature aging.

DiseaseLandscape Insights carries out comprehensive research on the management of Atopic Eczema to provide its clients with a competitive edge. DLI offers details about new medications, therapies, and therapy choices in addition to products and services. In addition, DLI develops novel therapy solutions for better patient health and conducts extensive research on rivals in the treatment industry.

The global industry for mobile video distribution is fiercely competitive and expanding. With their cutting-edge product names, the industry leaders mentioned below are pushing innovations and redefining the space in the quest for improved health results.

Treatment Market Players:



ICPA Health

Calovera 50ml

ICPA Health

Moyzen Cream 100gm

Glaxo Simthkline Pharmaceuticals Ltd

Oilatum Emollient



Menarini India Pvt Ltd.


Glaxo Simthkline Pharmaceuticals Ltd

Betnovate Cream & Ointment







Jubilant Cadista Pharmaceuticals Inc.




LEO Pharma Inc.





Recent Development:

On 20 October 2023, INDIANAPOLIS published that nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years. Lebrikizumab managed with a once-monthly dose following an induction phase, demonstrated efficacy for patients with moderate-to-severe atopic dermatitis, and offers a sustained relief from some of the most distressing signs and symptoms of the disease.

Lebrikizumab is an interleukin-13 (IL-13) inhibitor that specifically blocks IL-13 signaling. The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory loop in the skin, and causing skin barrier dysfunction, itch, skin thickening, and infection.

All in all, the key players have numerous opportunities in the treatment and diagnosis field. The existing players have generated tremendous income from the atopic dermatitis business. Such developments have increased the scope and economy of the atopic dermatitis disease market globally.

Regulatory Framework:

According to TGA (Therapeutic Goods Administration), on 29 August 2022 approved DUPIXENT, sponsored by Sanofi-Aventis Australia Pty Ltd. Dupixent is indicated for the following type 2 inflammatory diseases: Atopic Dermatitis and Prurigo nodularis as well as for add-on therapy in asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).

In Adults and adolescents, Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use. In children 6 to 11 years of age, Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.

Clinical Trial Assessment:

The government's growing focus on comparative effectiveness research highlights the significance of clinical trials for evidence-based medicine and healthcare reform. One of the main objectives of health care reform is accomplished with the aid of clinical data, which enables market participants to correctly compare medical therapy.

The table below lists the study names of the ongoing clinical trials along with the stages at which they are being carried out.

Phase 1

Phase 2

Phase 3

Phase 4

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single and Multiple Ascending Doses of FRTX-02 in Healthy Subjects and Subjects with Atopic Dermatitis

A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects with Atopic Eczema

The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator

A 3-Month Open Label, National, Quality of Life, and Safety Study with Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis

Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients

The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator

A multi-center, Parallel, Randomised Study of the Skin Tolerance of Betamethasone Creams on Atopic Eczema and the Influence of Moisturiser Treatment on the Recurrence of Eczema

Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescent Patients with Atopic Dermatitis: A Non-inferiority Randomized Trial

An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients with Atopic Dermatitis

SEAL (Stopping Eczema and ALlergy) Study: Prevent the Allergic March by Enhancing the Skin Barrier

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis

Monitoring Response to Therapy in Atopic Dermatitis Patients Treated with Dupilumab Using Noninvasive Reflectance Confocal Microscopy and Optical Coherence Tomography

An Open-label, Multicenter, Phase Ib Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects Aged 2 to 17 Years with Atopic Dermatitis

Single-Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair®) Treatment in Atopic Dermatitis

A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

The Pathogenic Role of Staphylococcus Aureus and The Skin Microbiome During Flare and Resolution of Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of HAT01H, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-controlled Clinical Trial in Patients with Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects with Moderate Atopic Dermatitis

8-Week Atopic Dermatitis (AD) Treatment Study

DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients with Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry



Manufacturers are helped by DiseaseLandscape Insights (DLI) in creating and executing workable solutions to stop and control Atopic Dermatitis outbreaks. In addition, increased awareness and predicted epidemics have led to a growing demand for improved medicines, clinical assessments, and diagnostic technologies.

DiseaseLandscape Insights provides key players in the production of medicinal items with vital information and experience. With the help of DiseaseLandscape Insights, market participants more easily plan and execute clinical trials for novel drugs and pharmaceuticals, patient recruitment strategies, and regulatory compliance.

All in all, this motivates the leaders to investigate manufacturing companies, do qualitative research, and find out about raw material suppliers. DLI services help all industry participants maintain a competitive edge and get a greater footing in Atopic Dermatitis.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape